Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of hypertension includes epidemiological estimates for key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s hypertension forecast will answer the following questions:

  • Of all people with hypertension, how many in each country under study have been formally diagnosed?
  • Of all people diagnosed with hypertension, how many in each country under study are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hypertension over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 28 hypertension patient populations, including the following:

  • Total prevalent cases of hypertension
  • Total prevalent cases of hypertension (per ACC/AHA 2017)
  • Total prevalent cases of prehypertension
  • Diagnosed prevalent cases of hypertension
  • Diagnosed drug-treated prevalent cases of hypertension
  • Diagnosed drug-treated-controlled prevalent cases of hypertension
  • Diagnosed drug-treated-controlled prevalent cases of hypertension on 1 antihypertensive
  • Diagnosed drug-treated-controlled prevalent cases of hypertension on 2 antihypertensives
  • Diagnosed drug-treated-controlled prevalent cases of hypertension on 3 antihypertensives
  • Diagnosed drug-treated-controlled prevalent cases of hypertension on > =4 antihypertensives
  • … and many more (details available on request).

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Psoriasis – Access & Reimbursement – Access & Reimbursement – Psoriasis (US)
The U.S. psoriasis treatment landscape is rapidly evolving, with newer, more effective therapies increasing competition for favorable MCO coverage, further intensified by the introduction of…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing…